title: Four-day continuous gastric pH monitoring following anti-acid secretory drug administration: cross-over test to assess the early effects.
abstract: BACKGROUND
  There have been few reports that compare the effect of histamine H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) using continuous gastric pH monitoring for a long duration.
  
  
  OBJECTIVE
  To assess the early effects of both drugs on gastric pH using a wireless pH monitoring system.
  
  
  METHODS
  The test was conducted by a cross-over test: 10 healthy male volunteers were administered famotidine 20 mg twice a day and lansoprazole 30 mg once a day. Monitoring of gastric pH over four consecutive days was performed using a unique method we have developed that is an elaboration of the Bravo system.
  
  
  RESULTS
  The time to reach a pH level of 3 or more with famotidine was significantly shorter than that for lansoprazole. The pH3 holding time ratio of famotidine during the first 4 h of administration was significantly higher than that of lansoprazole. The pH3 holding time ratio on each day from day 1 to day 3 was significantly higher following lansoprazole administration compared with famotidine administration.
  
  
  CONCLUSIONS
  Famotidine was shown to act quickly in elevating gastric pH; however, lansoprazole was superior to famotidine in terms of its ability to elevate gastric pH for a long duration.
authors.affiliation: Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. suzuki4511@yahoo.co.jp
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: T
authors.initials: T
authors.lastname: Odaka
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Seza
authors.forename: T
authors.initials: T
authors.lastname: Kouzu
authors.forename: O
authors.initials: O
authors.lastname: Yokosuka
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D018592:Cross-Over Studies; D015738:Famotidine / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D054328:Proton Pump Inhibitors / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D015738:Famotidine